Cytodyn Inc (CYDY)

[docj]

Fidelity news feed:

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
GlobeNewswire
8:30 AM ET May-11-2026
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (profile), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (N2B) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (BIIB.NaE) , Moderna Inc. (MRNA.NaE) , CytoDyn Inc. (CYDY.NaE) and Northwest Biotherapeutics Inc. (NWBO.NaE) .

Oncotelic Therapeutics is focused on advancing technologies designed to bypass or overcome BBB limitations.
The global burden of Alzheimer’s disease and related dementias is increasing at an unprecedented rate.
Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security.
As traditional drug-delivery approaches continue to face limitations, alternative methods designed to bypass the BBB, such as those being developed by Oncotelic, are gaining increasing attention.
The future of CNS therapeutics is increasingly centered on platform-based solutions rather than single-drug strategies.